Search: id:"swepub:oai:gup.ub.gu.se/269532" >
Levels of ADAM10 ar...
Levels of ADAM10 are reduced in Alzheimer's disease CSF
-
Sogorb-Esteve, A. (author)
-
Garcia-Ayllon, M. S. (author)
-
- Gobom, Johan (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
show more...
-
Alom, J. (author)
-
- Zetterberg, Henrik, 1973 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
- Blennow, Kaj, 1958 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Saez-Valero, J. (author)
-
show less...
-
(creator_code:org_t)
- 2018-07-25
- 2018
- English.
-
In: Journal of Neuroinflammation. - : Springer Science and Business Media LLC. - 1742-2094. ; 15
- Related links:
-
https://jneuroinflam...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: The disintegrin metalloproteinase 10 (ADAM10) is the main alpha-secretase acting in the non-amyloidogenic processing of the amyloid precursor protein. This study assesses whether ADAM10 is present in cerebrospinal fluid (CSF), and whether it has potential as a biomarker for Alzheimer's disease (AD). Methods: ADAM10 was characterized in human CSF samples by immunoprecipitation and western blotting using antibodies specific for different domains of the protein and by ultracentrifugation in sucrose density gradients. Samples from AD patients (n = 20) and age-matched non-AD controls (n = 20) were characterized for classical CSF biomarkers, A beta 42, T-tau, or P-tau by ELISA, and assayed for soluble ADAM10 levels by western blotting. Results: We found that ADAM10 is present in human CSF as several distinct species: an immature form retaining the prodomain (proADAM10; similar to 80 kDa), a mature unprocessed full-length form (ADAM10f; similar to 55 kDa), and a truncated large soluble form released from the membrane (sADAM10; similar to 50 kDa). Fractionation by ultracentrifugation on sucrose density gradients showed that the ADAM10f and sADAM10 species form large complexes. Immunoblotting revealed a significant decrease in ADAM10f and sADAM10 in AD CSF compared to control CSF, while proADAM10 levels remained unaltered. Conclusions: Several forms of ADAM10 are present in CSF, mainly assembled as high-molecular weight complexes. The determination of the levels of mature forms of CSF-ADAM10 may be useful as a biomarker for AD.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
Keyword
- amyloid precursor protein
- mild cognitive impairment
- alpha-secretase
- adam10
- human cerebrospinal-fluid
- tace activity
- bace1 activity
- disintegrin
- metalloprotease
- identification
- dimerization
- Immunology
- Neurosciences & Neurology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database